Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lluch

Showing results (21-30 of 186) with videos related to

Pageof 19
Sort By:
The Oncologist|May 16, 2012
High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patientsChandra Bartholomeusz, Ana M Gonzalez-Angulo, Ping Liu, et al.
Cancer Treatment Reviews|October 17, 2008
Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancerMontserrat Muñoz, Laura G Estévez, Isabel Alvarez, et al.
The Oncologist|April 3, 2012
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancerMiguel Martín, Anatoly Makhson, Joseph Gligorov, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|September 13, 2014
Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspectiveMiguel Ángel Seguí, Carlos Crespo, Javier Cortés, et al.
Cancer Treatment Reviews|October 4, 2005
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use ProgrammeGuenther G Steger, Maya Gips, Sergio D Simon, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 19, 2010
Supportive care for patients with early breast cancerLaura García-Estévez, Ignasi Tusquets, Isabel Alvarez, et al.
Cancer Treatment Reviews|May 14, 2010
Current perspectives of treatment of ductal carcinoma in situLaura G Estévez, Isabel Alvarez, Miguel Ángel Seguí, et al.
Cancers|July 9, 2022
Immunological Landscape of HER-2 Positive Breast CancerSantiago Moragon, Cristina Hernando, Maria Teresa Martinez-Martinez, et al.
Journal of Cellular Biochemistry|March 25, 2015
MicroRNA Profile in Response to Doxorubicin Treatment in Breast CancerEduardo Tormo, Begoña Pineda, Eva Serna, et al.
Melanoma Research|July 3, 2009
Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancerEduardo Nagore, Alegria Montoro, Zaida García-Casado, et al.
Pageof 19

Showing results (21-30 of 186) with videos related to

Sort By:
Pageof 19
The Oncologist|May 16, 2012
High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patientsChandra Bartholomeusz, Ana M Gonzalez-Angulo, Ping Liu, et al.
Cancer Treatment Reviews|October 17, 2008
Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancerMontserrat Muñoz, Laura G Estévez, Isabel Alvarez, et al.
The Oncologist|April 3, 2012
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancerMiguel Martín, Anatoly Makhson, Joseph Gligorov, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|September 13, 2014
Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspectiveMiguel Ángel Seguí, Carlos Crespo, Javier Cortés, et al.
Cancer Treatment Reviews|October 4, 2005
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use ProgrammeGuenther G Steger, Maya Gips, Sergio D Simon, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 19, 2010
Supportive care for patients with early breast cancerLaura García-Estévez, Ignasi Tusquets, Isabel Alvarez, et al.
Cancer Treatment Reviews|May 14, 2010
Current perspectives of treatment of ductal carcinoma in situLaura G Estévez, Isabel Alvarez, Miguel Ángel Seguí, et al.
Cancers|July 9, 2022
Immunological Landscape of HER-2 Positive Breast CancerSantiago Moragon, Cristina Hernando, Maria Teresa Martinez-Martinez, et al.
Journal of Cellular Biochemistry|March 25, 2015
MicroRNA Profile in Response to Doxorubicin Treatment in Breast CancerEduardo Tormo, Begoña Pineda, Eva Serna, et al.
Melanoma Research|July 3, 2009
Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancerEduardo Nagore, Alegria Montoro, Zaida García-Casado, et al.
Pageof 19